Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection.

PubWeight™: 2.11‹?› | Rank: Top 2%

🔗 View Article (PMC 2702159)

Published in PLoS Med on July 07, 2009

Authors

Marc C Levesque1, M Anthony Moody, Kwan-Ki Hwang, Dawn J Marshall, John F Whitesides, Joshua D Amos, Thaddeus C Gurley, Sallie Allgood, Benjamin B Haynes, Nathan A Vandergrift, Steven Plonk, Daniel C Parker, Myron S Cohen, Georgia D Tomaras, Paul A Goepfert, George M Shaw, Jörn E Schmitz, Joseph J Eron, Nicholas J Shaheen, Charles B Hicks, Hua-Xin Liao, Martin Markowitz, Garnett Kelsoe, David M Margolis, Barton F Haynes

Author Affiliations

1: Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America.

Articles citing this

The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99

Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. N Engl J Med (2016) 2.34

AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood (2010) 2.10

B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood (2010) 2.05

Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med (2011) 1.97

Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS (2010) 1.94

HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr Opin HIV AIDS (2009) 1.67

A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. Br J Dermatol (2015) 1.46

Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS (2014) 1.41

HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol (2009) 1.39

How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses (2011) 1.30

Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. J Clin Invest (2011) 1.27

HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. Mucosal Immunol (2013) 1.23

Evidence of early B-cell dysregulation in simian immunodeficiency virus infection: rapid depletion of naïve and memory B-cell subsets with delayed reconstitution of the naïve B-cell population. J Virol (2009) 1.22

Antigen-dependent and -independent mechanisms of T and B cell hyperactivation during chronic HIV-1 infection. J Virol (2011) 1.17

Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. AIDS (2011) 1.16

Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J Virol (2011) 1.13

B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends Mol Med (2010) 1.11

Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment. J Virol (2010) 1.07

Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques. J Virol (2012) 1.07

Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat Med (2014) 1.06

Characterization of plasmablasts in the blood of HIV-infected viremic individuals: evidence for nonspecific immune activation. J Virol (2013) 1.06

Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients. J Immunol (2013) 1.05

The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-β1 production and FcRL4 expression. Nat Immunol (2013) 1.04

Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med (2010) 1.02

Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques. J Virol (2013) 0.99

Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo. J Immunol (2010) 0.99

HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell Host Microbe (2014) 0.97

Immune responses to HIV and SIV in mucosal tissues: 'location, location, location'. Curr Opin HIV AIDS (2010) 0.96

Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination. Curr Opin HIV AIDS (2014) 0.95

Alterations of the B-cell response by HIV-1 replication. Curr HIV/AIDS Rep (2011) 0.95

Which Antibody Functions are Important for an HIV Vaccine? Front Immunol (2014) 0.94

Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional B-cell-activating factor receptor. J Virol (2010) 0.93

HIV-associated memory B cell perturbations. Vaccine (2015) 0.92

The humoral response to HIV-1: new insights, renewed focus. J Infect Dis (2010) 0.91

Simian immunodeficiency virus infection in rhesus macaques induces selective tissue specific B cell defects in double positive CD21+CD27+ memory B cells. Clin Immunol (2011) 0.91

Role of IL-21 and IL-21 receptor on B cells in HIV infection. Crit Rev Immunol (2012) 0.90

HIV Infection and Gut Mucosal Immune Function: Updates on Pathogenesis with Implications for Management and Intervention. Curr Infect Dis Rep (2010) 0.88

Effects of HIV-1 Tat on enteric neuropathogenesis. J Neurosci (2014) 0.87

Default in plasma and intestinal IgA responses during acute infection by simian immunodeficiency virus. Retrovirology (2012) 0.87

Cross-reactive broadly neutralizing antibodies: timing is everything. Front Immunol (2012) 0.86

Mucosal immunology of HIV infection. Immunol Rev (2013) 0.86

Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection. Retrovirology (2010) 0.85

The human intestinal IgA response; burning questions. Front Immunol (2012) 0.84

The intestinal B-cell response in celiac disease. Front Immunol (2012) 0.84

Characterization of functional antibody and memory B-cell responses to pH1N1 monovalent vaccine in HIV-infected children and youth. PLoS One (2015) 0.84

Determinants of vaccine immunogenicity in HIV-infected pregnant women: analysis of B and T cell responses to pandemic H1N1 monovalent vaccine. PLoS One (2015) 0.81

Lack of B cell dysfunction is associated with functional, gp120-dominant antibody responses in breast milk of simian immunodeficiency virus-infected African green monkeys. J Virol (2013) 0.81

Persistence and selection of an expanded B-cell clone in the setting of rituximab therapy for Sjögren's syndrome. Arthritis Res Ther (2014) 0.81

Plasmacytoid dendritic cells mediate synergistic effects of HIV and lipopolysaccharide on CD27+ IgD- memory B cell apoptosis. J Virol (2014) 0.81

B-cell responses to HIV infection. Immunol Rev (2017) 0.80

Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection. PLoS Comput Biol (2016) 0.79

Dysregulation of Systemic and Mucosal Humoral Responses to Microbial and Food Antigens as a Factor Contributing to Microbial Translocation and Chronic Inflammation in HIV-1 Infection. PLoS Pathog (2017) 0.78

Altered Memory Circulating T Follicular Helper-B Cell Interaction in Early Acute HIV Infection. PLoS Pathog (2016) 0.78

Cancer prevention in HIV-infected populations. Semin Oncol (2015) 0.77

Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection. AIDS Res Hum Retroviruses (2012) 0.77

Discrete partitioning of HIV-1 Env forms revealed by viral capture. Retrovirology (2015) 0.77

Destruction of lymphoid organ architecture and hepatitis caused by CD4+ T cells. PLoS One (2011) 0.77

Key differences in B cell activation patterns and immune correlates among treated HIV-infected patients versus healthy controls following influenza vaccination. Vaccine (2015) 0.77

Lack of viral control and development of combination antiretroviral therapy escape mutations in macaques after bone marrow transplantation. AIDS (2015) 0.77

Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization. Front Microbiol (2016) 0.76

CD4(+) T Follicular Helper and IgA(+) B Cell Numbers in Gut Biopsies from HIV-Infected Subjects on Antiretroviral Therapy Are Similar to HIV-Uninfected Individuals. Front Immunol (2016) 0.76

Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. Immunol Rev (2017) 0.76

Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. Immunol Rev (2017) 0.76

Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine. J AIDS Clin Res (2012) 0.76

High expression levels of BLyS/BAFF by blood dendritic cells and granulocytes are associated with B-cell dysregulation in SIV-infected rhesus macaques. PLoS One (2015) 0.76

Immune Responses to Circulating and Vaccine Viral Strains in HIV-Infected and Uninfected Children and Youth Who Received the 2013/2014 Quadrivalent Live-Attenuated Influenza Vaccine. Front Immunol (2016) 0.75

Dancing with an escape artist. Nature (2010) 0.75

Subversion of the B-cell compartment during parasitic, bacterial, and viral infections. BMC Immunol (2015) 0.75

Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques. PLoS One (2017) 0.75

Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success. Front Immunol (2017) 0.75

Massive plasmablast response elicited in the acute phase of Hantavirus Pulmonary Syndrome. Immunology (2017) 0.75

Effect of Antiretroviral Therapy on the Memory and Activation Profiles of B Cells in HIV-Infected African Women. J Immunol (2016) 0.75

Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies. Front Immunol (2017) 0.75

Divergent Expression of CXCR5 and CCR5 on CD4(+) T Cells and the Paradoxical Accumulation of T Follicular Helper Cells during HIV Infection. Front Immunol (2017) 0.75

Articles cited by this

Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38

Antibody neutralization and escape by HIV-1. Nature (2003) 21.48

CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55

Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science (1998) 12.81

Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90

Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med (1983) 10.09

Clonal selection and learning in the antibody system. Nature (1996) 9.58

Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 9.11

Adaptive immune features of natural killer cells. Nature (2009) 8.46

New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25

A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature (2008) 8.22

Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol (2003) 8.02

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med (2000) 7.48

Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med (2007) 6.13

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69

Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science (1993) 5.40

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol (2008) 5.24

Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood (2004) 5.10

Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol (2009) 4.98

Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science (1996) 4.72

Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol (2007) 4.13

Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A (2009) 3.74

Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med (2003) 3.48

Antigen-induced B-cell death and elimination during germinal-centre immune responses. Nature (1995) 2.95

Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature (2005) 2.89

Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J Immunol (1995) 2.72

Soluble antigen can cause enhanced apoptosis of germinal-centre B cells. Nature (1995) 2.65

HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A (2001) 2.54

Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood (2005) 2.50

HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med (1998) 2.50

The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol (2008) 2.44

Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J Immunol (1995) 2.42

The mucosal immune system: primary target for HIV infection and AIDS. Trends Immunol (2001) 2.38

Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS (2001) 2.28

Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjögren's syndrome. J Immunol (2001) 2.25

Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell (2007) 2.22

HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol (2006) 2.12

Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. J Virol (2007) 2.11

The immune response to thetaX 174 in man. I. Primary and secondary antibody production in normal adults. Clin Exp Immunol (1973) 2.10

Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science (1993) 2.08

Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol (2008) 2.01

Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol (2007) 1.96

In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. IV. Affinity-dependent, antigen-driven B cell apoptosis in germinal centers as a mechanism for maintaining self-tolerance. J Exp Med (1995) 1.94

Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis (2007) 1.91

Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS (2005) 1.87

Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest (1992) 1.84

Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. J Virol (2008) 1.69

Membrane tumour necrosis factor-alpha is involved in the polyclonal B-cell activation induced by HIV-infected human T cells. Nature (1993) 1.56

Spectrum of morphologic changes of lymph nodes from patients with AIDS or AIDS-related complexes. Prog Allergy (1986) 1.53

Determinants of disease in the simian immunodeficiency virus-infected rhesus macaque: characterizing animals with low antibody responses and rapid progression. J Gen Virol (1998) 1.51

Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol Rev (1994) 1.48

Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy. AIDS (2007) 1.43

B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol (2008) 1.40

Early human T cell development: analysis of the human thymus at the time of initial entry of hematopoietic stem cells into the fetal thymic microenvironment. J Exp Med (1995) 1.38

CD4+-T-cell and CD20+-B-cell changes predict rapid disease progression after simian-human immunodeficiency virus infection in macaques. J Virol (1998) 1.36

Elimination of chronic viral infection by blocking CD27 signaling. J Exp Med (2006) 1.32

Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. Mol Immunol (2005) 1.28

Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection. J Clin Invest (1999) 1.19

Early depletion of proliferating B cells of germinal center in rapidly progressive simian immunodeficiency virus infection. Virology (2007) 1.12

B-cell abnormalities in AIDS: stable and clonally-restricted antibody response in HIV-1 infection. Scand J Immunol (1993) 1.06

T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses. Nat Med (1998) 1.01

Defensins: natural anti-HIV peptides. AIDS Rev (2004) 0.99

Maintenance of serological memory. Biol Chem (2008) 0.98

Intestinal B cell hyperactivity in AIDS is controlled by highly active antiretroviral therapy. Gut (2004) 0.97

A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. Proc Natl Acad Sci U S A (1996) 0.96

Epstein-Barr virus preferentially induces proliferation of primed B cells. J Immunol (1989) 0.94

The varied histopathology of lymphadenopathy in the homosexual male. Am J Surg Pathol (1985) 0.94

Interleukin-15 enhances HIV-1-driven polyclonal B-cell response in vitro. Exp Clin Immunogenet (1999) 0.94

Follicular dendritic cells in HIV-induced lymphadenopathy and AIDS. APMIS Suppl (1989) 0.91

Antigen-specific B-lymphocyte activation. Crit Rev Immunol (2003) 0.90

Ultrastructural analysis of germinal centers in lymph nodes of patients with HIV-1-induced persistent generalized lymphadenopathy: evidence for persistence of infection. Prog AIDS Pathol (1989) 0.90

Spontaneous secretion of immunoglobulins and anti-HIV-1 antibodies by in vivo activated B lymphocytes from HIV-1-infected subjects: monocyte and natural killer cell requirement for in vitro terminal differentiation into plasma cells. Clin Immunol (2002) 0.90

Activation of cytotoxic cells in hyperplastic lymph nodes from HIV-infected patients. AIDS (1991) 0.89

Monoclonal antibodies to human immunodeficiency virus: their relation to the patterns of lymph node changes in persistent generalized lymphadenopathy and AIDS. AIDS (1987) 0.88

The immunohistology of lymph nodes in HIV infection: a review. Prog AIDS Pathol (1990) 0.86

The role of epithelial cells in gut-associated immune reactivity. Ann N Y Acad Sci (1983) 0.86

Immunohistochemical recognition of human follicular dendritic cells (FDCs) in routinely processed paraffin sections. J Histochem Cytochem (2002) 0.86

Similar abnormalities of idiotype and immunoglobulin light chain expression and of cell-mediated cytotoxicity in HIV-infected humans and simian immunodeficiency virus (SIV)-infected rhesus macaques. Immunol Cell Biol (1996) 0.84

Articles by these authors

Antibody neutralization and escape by HIV-1. Nature (2003) 21.48

Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54

A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91

Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature (2002) 12.49

Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol (2011) 12.48

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61

Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 9.11

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94

Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science (2004) 8.60

The challenge of finding a cure for HIV infection. Science (2009) 8.41

Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30

Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92

Detection of acute infections during HIV testing in North Carolina. N Engl J Med (2005) 7.60

Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature (2002) 7.41

Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20

Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology (2012) 7.15

Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science (2006) 7.12

Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med (2007) 7.12

The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol (2004) 7.04

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01

Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science (2006) 6.06

The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99

American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology (2011) 5.93

The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet (2011) 5.87

Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis (2008) 5.85

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79

Syphilis in China: results of a national surveillance programme. Lancet (2007) 5.76

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS (2009) 5.72

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69

Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA (2004) 5.66

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58

Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44

Population-based study of chlamydial infection in China: a hidden epidemic. JAMA (2003) 5.40

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35

Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet (2011) 5.34

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol (2008) 5.24

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89

HIV/AIDS risk among brothel-based female sex workers in China: assessing the terms, content, and knowledge of sex work. Sex Transm Dis (2004) 4.88

Acute HIV-1 Infection. N Engl J Med (2011) 4.84

Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82

Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79

Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol (2008) 4.73

Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70

Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68

Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol (2002) 4.65

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45

AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44

Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A (2004) 4.37

Origin of the human malaria parasite Plasmodium falciparum in gorillas. Nature (2010) 4.35

Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses (2009) 4.32

HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23

Quality indicators for colonoscopy. Gastrointest Endosc (2014) 4.17

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06